MISGAV, Israel, July 18, 2017 /PRNewswire/ — Medical device company ApiFix, a portfolio company of The Trendlines Group (SGX: 42T; OTCQX: TRNLY), announced it inked an exclusive distribution deal in Spain with Acuna-Fombona, a distributor of Spain and Portugal. The first scoliosis correction surgery was performed in Hospital Universitari Sagrat Cor, Barcelona (Spain)Hospital, Spain by Dr. Juan Carlos Olaverri.
ApiFix has developed a minimally invasive, non-fusion spinal implant system for the correction of Adolescent Idiopathic Scoliosis (AIS). ApiFix improves the quality of life of patients who undergo scoliosis surgery, saves hospitalization and OR time, and costs substantially less than standard scoliosis surgery.
“When Acuna Fombona learned about the ApiFix system, we immediately recognized that the technology is a game-changer for AIS patients. We are thrilled to exclusively represent ApiFix with their non-fusion solution to surgeons and patients alike,” stated Acuna-Fombona CEO, Sergio Fombona
Current scoliosis surgical correction is a highly invasive, lengthy surgical procedure involving fusion, and resulting in a rigid spine with long recovery period. The ApiFix system is a market disruptor with its minimally invasive, non-fusion spinal implant system, inserted in a short procedure, followed by a brief recovery period, and maintains spine flexibility.
ApiFix CEO Eran Feldhay, M.D. remarked: “We are excited to continue our expansion in Europe and to add Spain to the growing list of European countries where we distribute and perform surgeries with the ApiFix system. The Spanish market is important to us and we are proud to offer our products to Spanish AIS patients.”
About ApiFix
ApiFix is an innovation-driven medical device company focused on providing less invasive solutions for scoliosis patients. ApiFix’s leading product for non-fusion treatment of adolescent idiopathic scoliosis (AIS) is used today in Europe. ApiFix is led by a team of highly-regarded spine surgeons and veteran spine specialists. The company has CE clearance and is marketed in Germany, Italy, Greece, The Netherlands and Israel.
ApiFix principals will attend the annual meeting of the Scoliosis Research Society, (SRS) in Philadelphia, USA on September 5-8 to present the ApiFix system, clinical cases and their follow-up to potential users from all over the world.
Contact: Saar Wollach, ApiFix Sales & Marketing Manager, +972-54-4511512, Philadelphia [email protected]